Phase I Study of MT1011 Injection in Healthy Subjects

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation

In brief

This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.

Key facts

Study ID
NCT07024160
Run by
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
People needed
40
Starts
2025-06-25
Expected to finish
2026-04-01
Last updated by the study team
2025-07-03

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.